Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5695268 | Gynecologic Oncology | 2017 | 7 Pages |
Abstract
This is the only large multicentre study published so far on TCS in EOC with â¥Â 6 month TFI. The achievement of postoperative no residual disease is confirmed as the primary objective also in a TCS setting, with significant survival benefit and acceptable morbidity. Accurate patient selection is of utmost importance to have the best chance of complete cytoreduction.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
F. Falcone, G. Scambia, P. Benedetti Panici, M. Signorelli, G. Cormio, G. Giorda, S. Bogliolo, M. Marinaccio, F. Ghezzi, E. Rabaiotti, E. Breda, G. Casella, F. Fanfani, V. Di Donato, U. Leone Roberti Maggiore, S. Greggi,